Business Description
Stoke Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US86150R1077
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 97.67 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.5 | |||||
Beneish M-Score | -4.11 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -17.9 | |||||
3-Year EPS without NRI Growth Rate | -15.1 | |||||
3-Year FCF Growth Rate | -13.3 | |||||
3-Year Book Growth Rate | -23.7 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53 | |||||
9-Day RSI | 52.69 | |||||
14-Day RSI | 55.68 | |||||
6-1 Month Momentum % | 197.5 | |||||
12-1 Month Momentum % | 34.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.99 | |||||
Quick Ratio | 6.99 | |||||
Cash Ratio | 6.53 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 | |||||
Shareholder Yield % | -7.18 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1307.05 | |||||
Net Margin % | -1192.34 | |||||
FCF Margin % | -936.08 | |||||
ROE % | -56.81 | |||||
ROA % | -41.45 | |||||
ROIC % | -374.62 | |||||
ROC (Joel Greenblatt) % | -1057.38 | |||||
ROCE % | -51.14 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 59.5 | |||||
PB Ratio | 3.46 | |||||
Price-to-Tangible-Book | 3.45 | |||||
EV-to-EBIT | -3.72 | |||||
EV-to-Forward-EBIT | -0.1 | |||||
EV-to-EBITDA | -3.8 | |||||
EV-to-Forward-EBITDA | -3.33 | |||||
EV-to-Revenue | 48.64 | |||||
EV-to-Forward-Revenue | 31.53 | |||||
EV-to-FCF | -5.17 | |||||
Price-to-Net-Current-Asset-Value | 3.77 | |||||
Price-to-Net-Cash | 4.16 | |||||
Earnings Yield (Greenblatt) % | -26.88 | |||||
FCF Yield % | -13.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Stoke Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 8.191 | ||
EPS (TTM) (€) | -2.197 | ||
Beta | 0.72 | ||
Volatility % | 121.48 | ||
14-Day RSI | 55.68 | ||
14-Day ATR (€) | 0.577498 | ||
20-Day SMA (€) | 11.18 | ||
12-1 Month Momentum % | 34.46 | ||
52-Week Range (€) | 3.14 - 12.9 | ||
Shares Outstanding (Mil) | 52.12 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Stoke Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Stoke Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Stoke Therapeutics Inc Frequently Asked Questions
What is Stoke Therapeutics Inc(STU:0GT)'s stock price today?
When is next earnings date of Stoke Therapeutics Inc(STU:0GT)?
Does Stoke Therapeutics Inc(STU:0GT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |